CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)

Larger Vial Size Is Another Convenience Offering for People Managing Primary Immunodeficiency with Hizentra KING OF PRUSSIA, Pa., Sept. 3, 2013 -- (Healthcare Sales & Marketing Network) -- CSL Behring today announced that the U.S. Food and Drug Adminis... Biopharmaceuticals, FDACSL Behring, Hizentra, Immune Globulin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news